Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10789031 | 0.85 | CA2 (0.52) | CA2CA1CA7CA13MAPK1 | |
| SCHEMBL627731 | 0.80 | CA2 (0.48) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL18158144 | 0.74 | CA2 (0.42) | CA2CA1MAPK1SMN1; SMN2 | |
| SCHEMBL25708327 | 0.74 | CA2 (0.52) | CA2CA1CA7CA13MAPK1 | |
| SCHEMBL183324 | 0.73 | CA2 (0.46) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL27547666 | 0.73 | CA2 (0.41) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL31602228 | 0.73 | CA1 (0.41) | CA2CA1MAPK1SMN1; SMN2 | |
| SCHEMBL17853345 | 0.73 | CA1 (0.41) | CA2CA1MAPK1SMN1; SMN2TGFBR1 | |
| SCHEMBL19019137 | 0.72 | CA1 (0.50) | CA2CA1CA7CA13MAPK1 | |
| SCHEMBL19810864 | 0.72 | CA1 (0.50) | CA2CA1CA7CA13MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | claimed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| EP-0010844-A1 | Novel N,N'-bis(trifluoromethylsulfonyl)oxamides, chemiluminescent compositions containing them and processes for generating chemiluminescence employing said compositions | AMERICAN CYANAMID COMPANY (US) | 1980-05-14 | — | — | EP | claimed |
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| US-4407743-A | REACTION WITH PEROXIDE IN PRESENCE OF FLUORESCER | AMERICAN CYANAMID COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0034261-A2 | Aqueous chemiluminescent systems | AMERICAN CYANAMID COMPANY (US) | 1981-08-26 | — | — | EP | disclosed |
| EP-0034261-A2 | Aqueous chemiluminescent systems | AMERICAN CYANAMID COMPANY (US) | 1981-08-26 | — | — | EP | disclosed |
| EP-0010844-A1 | Novel N,N'-bis(trifluoromethylsulfonyl)oxamides, chemiluminescent compositions containing them and processes for generating chemiluminescence employing said compositions | AMERICAN CYANAMID COMPANY (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NR1H4, SLC10A1, CYP46A1 | CA2 794/4885CA1 124/4885F2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.